Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-03-07

AUTHORS

Leslie R. Harrold, Bradley S. Stolshek, Sabrina Rebello, David H. Collier, Alex Mutebi, Sally W. Wade, Wendi Malley, Jeffrey D. Greenberg, Carol J. Etzel

ABSTRACT

Psoriatic arthritis (PsA) is a chronic condition characterized by a diverse set of symptoms, from swollen joints to nail disease to skin disease. A variety of treatment options are available, including tumor necrosis factor inhibitors (TNFis). Little is known about treatment persistence in patients with PsA who initiate TNFi therapy, with and without prior biologic use. This study assessed persistence in these subgroups of patients with PsA and identified factors associated with persistence. This retrospective study utilized data from the Corrona registry of patients with PsA—with or without prior biologic experience—who initiated TNFi therapy between October 1, 2002, and March 21, 2013. Kaplan-Meier curves estimated median time to nonpersistence (discontinuation or switch to another biologic). Cox proportional hazards models identified factors associated with TNFi nonpersistence. A total of 1241 TNFi initiations were identified: 549 by biologic-naïve and 692 by biologic-experienced patients. Through 4 years of follow-up, more biologic-naïve than biologic-experienced patients remained persistent. Biologic-naïve patients had a greater mean time to nonpersistence compared with biologic-experienced patients: 32 vs 23 months (p = 0.0002). Moderate and high disease activities based on clinical disease activity index and disease duration were associated with persistence in both biologic-naïve and biologic-experienced patients. Additionally, in the biologic-experienced patients, the number of prior medications and skin disease were associated with persistence. The majority of patients with PsA in this study were persistent with their TNFi therapy; biologic-naïve patients had greater persistence compared with biologic-experienced patients. Predictors of persistence differed slightly between biologic-naïve and biologic-experienced patients. More... »

PAGES

895-901

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10067-017-3593-x

DOI

http://dx.doi.org/10.1007/s10067-017-3593-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084023725

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28271234


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Psoriatic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Products", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Registries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, University of Massachusetts Medical School, AC7-201, 55 Lake Avenue North, 01655, Worcester, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.168645.8", 
          "name": [
            "Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA", 
            "Department of Medicine, University of Massachusetts Medical School, AC7-201, 55 Lake Avenue North, 01655, Worcester, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harrold", 
        "givenName": "Leslie R.", 
        "id": "sg:person.0736771744.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736771744.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stolshek", 
        "givenName": "Bradley S.", 
        "id": "sg:person.01047467057.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047467057.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rebello", 
        "givenName": "Sabrina", 
        "id": "sg:person.014625266551.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014625266551.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Collier", 
        "givenName": "David H.", 
        "id": "sg:person.0643276502.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643276502.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mutebi", 
        "givenName": "Alex", 
        "id": "sg:person.0747353025.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747353025.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wade", 
        "givenName": "Sally W.", 
        "id": "sg:person.0617012057.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malley", 
        "givenName": "Wendi", 
        "id": "sg:person.014200421247.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200421247.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University School of Medicine, 301 East 17th Street, Suite 1410, 10003, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA", 
            "New York University School of Medicine, 301 East 17th Street, Suite 1410, 10003, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greenberg", 
        "givenName": "Jeffrey D.", 
        "id": "sg:person.014444070377.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014444070377.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA", 
            "Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Etzel", 
        "givenName": "Carol J.", 
        "id": "sg:person.01257177671.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257177671.69"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/ar3249", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053673056", 
          "https://doi.org/10.1186/ar3249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2474-10-91", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039263381", 
          "https://doi.org/10.1186/1471-2474-10-91"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar1881", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013480577", 
          "https://doi.org/10.1186/ar1881"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2474-12-204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007982993", 
          "https://doi.org/10.1186/1471-2474-12-204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrrheum.2015.8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008800983", 
          "https://doi.org/10.1038/nrrheum.2015.8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-015-0697-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012494697", 
          "https://doi.org/10.1186/s13075-015-0697-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03-07", 
    "datePublishedReg": "2017-03-07", 
    "description": "Psoriatic arthritis (PsA) is a chronic condition characterized by a diverse set of symptoms, from swollen joints to nail disease to skin disease. A variety of treatment options are available, including tumor necrosis factor inhibitors (TNFis). Little is known about treatment persistence in patients with PsA who initiate TNFi therapy, with and without prior biologic use. This study assessed persistence in these subgroups of patients with PsA and identified factors associated with persistence. This retrospective study utilized data from the Corrona registry of patients with PsA\u2014with or without prior biologic experience\u2014who initiated TNFi therapy between October 1, 2002, and March 21, 2013. Kaplan-Meier curves estimated median time to nonpersistence (discontinuation or switch to another biologic). Cox proportional hazards models identified factors associated with TNFi nonpersistence. A total of 1241 TNFi initiations were identified: 549 by biologic-na\u00efve and 692 by biologic-experienced patients. Through 4\u00a0years of follow-up, more biologic-na\u00efve than biologic-experienced patients remained persistent. Biologic-na\u00efve patients had a greater mean time to nonpersistence compared with biologic-experienced patients: 32 vs 23\u00a0months (p\u00a0=\u00a00.0002). Moderate and high disease activities based on clinical disease activity index and disease duration were associated with persistence in both biologic-na\u00efve and biologic-experienced patients. Additionally, in the biologic-experienced patients, the number of prior medications and skin disease were associated with persistence. The majority of patients with PsA in this study were persistent with their TNFi therapy; biologic-na\u00efve patients had greater persistence compared with biologic-experienced patients. Predictors of persistence differed slightly between biologic-na\u00efve and biologic-experienced patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10067-017-3593-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1093299", 
        "issn": [
          "0770-3198", 
          "1434-9949"
        ], 
        "name": "Clinical Rheumatology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "biologic-experienced patients", 
      "biologic-na\u00efve", 
      "biologics-experienced patients", 
      "biologic-na\u00efve patients", 
      "prior biologic use", 
      "TNFi therapy", 
      "Corrona registry", 
      "psoriatic arthritis", 
      "biologic use", 
      "Clinical Disease Activity Index", 
      "tumor necrosis factor inhibitors", 
      "Kaplan-Meier curves", 
      "prior biologic experience", 
      "US Corrona registry", 
      "high disease activity", 
      "necrosis factor inhibitors", 
      "Disease Activity Index", 
      "majority of patients", 
      "subgroup of patients", 
      "persistence of treatment", 
      "proportional hazards model", 
      "greater mean time", 
      "predictors of persistence", 
      "TNFi initiation", 
      "prior medication", 
      "swollen joints", 
      "disease activity", 
      "disease duration", 
      "treatment persistence", 
      "median time", 
      "retrospective study", 
      "factor inhibitors", 
      "treatment options", 
      "biologic experience", 
      "chronic conditions", 
      "patients", 
      "hazards model", 
      "skin diseases", 
      "activity index", 
      "PSA", 
      "therapy", 
      "identified factors", 
      "mean time", 
      "disease", 
      "arthritis", 
      "nonpersistence", 
      "registry", 
      "medications", 
      "symptoms", 
      "persistence", 
      "study", 
      "months", 
      "na\u00efve", 
      "factors", 
      "subgroups", 
      "treatment", 
      "total", 
      "predictors", 
      "duration", 
      "greater persistence", 
      "inhibitors", 
      "majority", 
      "options", 
      "years", 
      "initiation", 
      "use", 
      "joints", 
      "index", 
      "activity", 
      "time", 
      "experience", 
      "data", 
      "number", 
      "impact", 
      "curves", 
      "variety", 
      "conditions", 
      "model", 
      "diverse set", 
      "set", 
      "TNFi nonpersistence"
    ], 
    "name": "Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry", 
    "pagination": "895-901", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084023725"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10067-017-3593-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28271234"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10067-017-3593-x", 
      "https://app.dimensions.ai/details/publication/pub.1084023725"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_751.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10067-017-3593-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10067-017-3593-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10067-017-3593-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10067-017-3593-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10067-017-3593-x'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      22 PREDICATES      131 URIs      117 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10067-017-3593-x schema:about N0cf5cdc6506a4f329b25671a39c1d2cd
2 N15b2fa4c3e514fc0b8844e78158c3f44
3 N17a0a5a0354e43029565b6fdcd27136a
4 N2f6410ae41cd452db145e11775f73ce0
5 N360c0d87958e443ea0276800874c4d8d
6 N44c2193dd76d4e1db265bc4094b13db6
7 N4efb4097be1b4f4a9de8bf20a369adda
8 N56d25df7af494e2f9e46907efeba7788
9 N5cc1ce2f2e6145dea5856096c5e30fff
10 N81d42e29226f42bdb6c3ce3d6e11db3b
11 N8d935d8fef634eb6aae54e7cd998b043
12 N9022a9a5e188419793343c0e912db8c0
13 N99551d8a693b42daa124e1180eb41912
14 N9c89b776291b4e3f82bc25bd877e8c93
15 Nad378c4dcd704075a8e884098dd48487
16 Nbd3a12c2f3cc4ccf9ebabd4a60e4abab
17 Nd1efc009eb544529923151772e3fbcb1
18 Nf1d3a97e2668468ba54a23b353372e35
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author N74be5f53f2a04f4a8ff5bb184730c37d
22 schema:citation sg:pub.10.1038/nrrheum.2015.8
23 sg:pub.10.1186/1471-2474-10-91
24 sg:pub.10.1186/1471-2474-12-204
25 sg:pub.10.1186/ar1881
26 sg:pub.10.1186/ar3249
27 sg:pub.10.1186/s13075-015-0697-z
28 schema:datePublished 2017-03-07
29 schema:datePublishedReg 2017-03-07
30 schema:description Psoriatic arthritis (PsA) is a chronic condition characterized by a diverse set of symptoms, from swollen joints to nail disease to skin disease. A variety of treatment options are available, including tumor necrosis factor inhibitors (TNFis). Little is known about treatment persistence in patients with PsA who initiate TNFi therapy, with and without prior biologic use. This study assessed persistence in these subgroups of patients with PsA and identified factors associated with persistence. This retrospective study utilized data from the Corrona registry of patients with PsA—with or without prior biologic experience—who initiated TNFi therapy between October 1, 2002, and March 21, 2013. Kaplan-Meier curves estimated median time to nonpersistence (discontinuation or switch to another biologic). Cox proportional hazards models identified factors associated with TNFi nonpersistence. A total of 1241 TNFi initiations were identified: 549 by biologic-naïve and 692 by biologic-experienced patients. Through 4 years of follow-up, more biologic-naïve than biologic-experienced patients remained persistent. Biologic-naïve patients had a greater mean time to nonpersistence compared with biologic-experienced patients: 32 vs 23 months (p = 0.0002). Moderate and high disease activities based on clinical disease activity index and disease duration were associated with persistence in both biologic-naïve and biologic-experienced patients. Additionally, in the biologic-experienced patients, the number of prior medications and skin disease were associated with persistence. The majority of patients with PsA in this study were persistent with their TNFi therapy; biologic-naïve patients had greater persistence compared with biologic-experienced patients. Predictors of persistence differed slightly between biologic-naïve and biologic-experienced patients.
31 schema:genre article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N070f0ff89b26458f8b310a74580cafe8
35 N3c082c7aee8e4bc9aebca9ee6ff3acca
36 sg:journal.1093299
37 schema:keywords Clinical Disease Activity Index
38 Corrona registry
39 Disease Activity Index
40 Kaplan-Meier curves
41 PSA
42 TNFi initiation
43 TNFi nonpersistence
44 TNFi therapy
45 US Corrona registry
46 activity
47 activity index
48 arthritis
49 biologic experience
50 biologic use
51 biologic-experienced patients
52 biologic-naïve
53 biologic-naïve patients
54 biologics-experienced patients
55 chronic conditions
56 conditions
57 curves
58 data
59 disease
60 disease activity
61 disease duration
62 diverse set
63 duration
64 experience
65 factor inhibitors
66 factors
67 greater mean time
68 greater persistence
69 hazards model
70 high disease activity
71 identified factors
72 impact
73 index
74 inhibitors
75 initiation
76 joints
77 majority
78 majority of patients
79 mean time
80 median time
81 medications
82 model
83 months
84 naïve
85 necrosis factor inhibitors
86 nonpersistence
87 number
88 options
89 patients
90 persistence
91 persistence of treatment
92 predictors
93 predictors of persistence
94 prior biologic experience
95 prior biologic use
96 prior medication
97 proportional hazards model
98 psoriatic arthritis
99 registry
100 retrospective study
101 set
102 skin diseases
103 study
104 subgroup of patients
105 subgroups
106 swollen joints
107 symptoms
108 therapy
109 time
110 total
111 treatment
112 treatment options
113 treatment persistence
114 tumor necrosis factor inhibitors
115 use
116 variety
117 years
118 schema:name Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry
119 schema:pagination 895-901
120 schema:productId N4bd9a587aee44b1ba9fca59c38011707
121 N7acdf6ba9879427eae4f793d26a317f1
122 N984f04c3eac942878b92877d8f6ecd3d
123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084023725
124 https://doi.org/10.1007/s10067-017-3593-x
125 schema:sdDatePublished 2022-01-01T18:45
126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
127 schema:sdPublisher N804ed3d8d6224d438255cbc83908707a
128 schema:url https://doi.org/10.1007/s10067-017-3593-x
129 sgo:license sg:explorer/license/
130 sgo:sdDataset articles
131 rdf:type schema:ScholarlyArticle
132 N070f0ff89b26458f8b310a74580cafe8 schema:issueNumber 4
133 rdf:type schema:PublicationIssue
134 N0cf5cdc6506a4f329b25671a39c1d2cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N15b2fa4c3e514fc0b8844e78158c3f44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Registries
139 rdf:type schema:DefinedTerm
140 N17a0a5a0354e43029565b6fdcd27136a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name United States
142 rdf:type schema:DefinedTerm
143 N1c3ebc49306a41eb8120f139daa4e779 rdf:first sg:person.014444070377.20
144 rdf:rest Nebb09f6087504650b6c1bdf9af9ad6b1
145 N2f6410ae41cd452db145e11775f73ce0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Antirheumatic Agents
147 rdf:type schema:DefinedTerm
148 N360c0d87958e443ea0276800874c4d8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Severity of Illness Index
150 rdf:type schema:DefinedTerm
151 N3c082c7aee8e4bc9aebca9ee6ff3acca schema:volumeNumber 36
152 rdf:type schema:PublicationVolume
153 N44c2193dd76d4e1db265bc4094b13db6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Tumor Necrosis Factor-alpha
155 rdf:type schema:DefinedTerm
156 N48677b0388e546898c6ba1f8beb67bb4 rdf:first sg:person.014625266551.18
157 rdf:rest Nf18a4ddb8b414c40af1e442a47753f68
158 N4bd9a587aee44b1ba9fca59c38011707 schema:name dimensions_id
159 schema:value pub.1084023725
160 rdf:type schema:PropertyValue
161 N4efb4097be1b4f4a9de8bf20a369adda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Female
163 rdf:type schema:DefinedTerm
164 N56d25df7af494e2f9e46907efeba7788 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Treatment Outcome
166 rdf:type schema:DefinedTerm
167 N5cc1ce2f2e6145dea5856096c5e30fff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Disease Progression
169 rdf:type schema:DefinedTerm
170 N74be5f53f2a04f4a8ff5bb184730c37d rdf:first sg:person.0736771744.12
171 rdf:rest Nd79cf0420133444e959ddcef90bb7376
172 N7acdf6ba9879427eae4f793d26a317f1 schema:name pubmed_id
173 schema:value 28271234
174 rdf:type schema:PropertyValue
175 N804ed3d8d6224d438255cbc83908707a schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 N81d42e29226f42bdb6c3ce3d6e11db3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Time Factors
179 rdf:type schema:DefinedTerm
180 N8d88f0849a614ffaa460eda6e35c118e rdf:first sg:person.0747353025.27
181 rdf:rest Na4cf5c02879e48e08d64ed68b4c3cb68
182 N8d935d8fef634eb6aae54e7cd998b043 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Proportional Hazards Models
184 rdf:type schema:DefinedTerm
185 N9022a9a5e188419793343c0e912db8c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Male
187 rdf:type schema:DefinedTerm
188 N984f04c3eac942878b92877d8f6ecd3d schema:name doi
189 schema:value 10.1007/s10067-017-3593-x
190 rdf:type schema:PropertyValue
191 N99551d8a693b42daa124e1180eb41912 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Retrospective Studies
193 rdf:type schema:DefinedTerm
194 N9c89b776291b4e3f82bc25bd877e8c93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Arthritis, Psoriatic
196 rdf:type schema:DefinedTerm
197 Na4cf5c02879e48e08d64ed68b4c3cb68 rdf:first sg:person.0617012057.00
198 rdf:rest Ne2a5487cda5040c786c037d92635b119
199 Nad378c4dcd704075a8e884098dd48487 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Kaplan-Meier Estimate
201 rdf:type schema:DefinedTerm
202 Nbd3a12c2f3cc4ccf9ebabd4a60e4abab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Biological Products
204 rdf:type schema:DefinedTerm
205 Nd1efc009eb544529923151772e3fbcb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Adult
207 rdf:type schema:DefinedTerm
208 Nd79cf0420133444e959ddcef90bb7376 rdf:first sg:person.01047467057.99
209 rdf:rest N48677b0388e546898c6ba1f8beb67bb4
210 Ne2a5487cda5040c786c037d92635b119 rdf:first sg:person.014200421247.34
211 rdf:rest N1c3ebc49306a41eb8120f139daa4e779
212 Nebb09f6087504650b6c1bdf9af9ad6b1 rdf:first sg:person.01257177671.69
213 rdf:rest rdf:nil
214 Nf18a4ddb8b414c40af1e442a47753f68 rdf:first sg:person.0643276502.79
215 rdf:rest N8d88f0849a614ffaa460eda6e35c118e
216 Nf1d3a97e2668468ba54a23b353372e35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Middle Aged
218 rdf:type schema:DefinedTerm
219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
220 schema:name Medical and Health Sciences
221 rdf:type schema:DefinedTerm
222 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
223 schema:name Clinical Sciences
224 rdf:type schema:DefinedTerm
225 sg:journal.1093299 schema:issn 0770-3198
226 1434-9949
227 schema:name Clinical Rheumatology
228 schema:publisher Springer Nature
229 rdf:type schema:Periodical
230 sg:person.01047467057.99 schema:affiliation grid-institutes:grid.417886.4
231 schema:familyName Stolshek
232 schema:givenName Bradley S.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047467057.99
234 rdf:type schema:Person
235 sg:person.01257177671.69 schema:affiliation grid-institutes:None
236 schema:familyName Etzel
237 schema:givenName Carol J.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257177671.69
239 rdf:type schema:Person
240 sg:person.014200421247.34 schema:affiliation grid-institutes:None
241 schema:familyName Malley
242 schema:givenName Wendi
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200421247.34
244 rdf:type schema:Person
245 sg:person.014444070377.20 schema:affiliation grid-institutes:grid.137628.9
246 schema:familyName Greenberg
247 schema:givenName Jeffrey D.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014444070377.20
249 rdf:type schema:Person
250 sg:person.014625266551.18 schema:affiliation grid-institutes:None
251 schema:familyName Rebello
252 schema:givenName Sabrina
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014625266551.18
254 rdf:type schema:Person
255 sg:person.0617012057.00 schema:affiliation grid-institutes:None
256 schema:familyName Wade
257 schema:givenName Sally W.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
259 rdf:type schema:Person
260 sg:person.0643276502.79 schema:affiliation grid-institutes:grid.417886.4
261 schema:familyName Collier
262 schema:givenName David H.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643276502.79
264 rdf:type schema:Person
265 sg:person.0736771744.12 schema:affiliation grid-institutes:grid.168645.8
266 schema:familyName Harrold
267 schema:givenName Leslie R.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736771744.12
269 rdf:type schema:Person
270 sg:person.0747353025.27 schema:affiliation grid-institutes:grid.417886.4
271 schema:familyName Mutebi
272 schema:givenName Alex
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747353025.27
274 rdf:type schema:Person
275 sg:pub.10.1038/nrrheum.2015.8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008800983
276 https://doi.org/10.1038/nrrheum.2015.8
277 rdf:type schema:CreativeWork
278 sg:pub.10.1186/1471-2474-10-91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039263381
279 https://doi.org/10.1186/1471-2474-10-91
280 rdf:type schema:CreativeWork
281 sg:pub.10.1186/1471-2474-12-204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007982993
282 https://doi.org/10.1186/1471-2474-12-204
283 rdf:type schema:CreativeWork
284 sg:pub.10.1186/ar1881 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013480577
285 https://doi.org/10.1186/ar1881
286 rdf:type schema:CreativeWork
287 sg:pub.10.1186/ar3249 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053673056
288 https://doi.org/10.1186/ar3249
289 rdf:type schema:CreativeWork
290 sg:pub.10.1186/s13075-015-0697-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1012494697
291 https://doi.org/10.1186/s13075-015-0697-z
292 rdf:type schema:CreativeWork
293 grid-institutes:None schema:alternateName Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA
294 Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
295 Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA
296 schema:name Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA
297 Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
298 Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA
299 rdf:type schema:Organization
300 grid-institutes:grid.137628.9 schema:alternateName New York University School of Medicine, 301 East 17th Street, Suite 1410, 10003, New York, NY, USA
301 schema:name Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA
302 New York University School of Medicine, 301 East 17th Street, Suite 1410, 10003, New York, NY, USA
303 rdf:type schema:Organization
304 grid-institutes:grid.168645.8 schema:alternateName Department of Medicine, University of Massachusetts Medical School, AC7-201, 55 Lake Avenue North, 01655, Worcester, MA, USA
305 schema:name Corrona, LLC, 325 Turnpike Road, Suite 325, 01772, Southborough, MA, USA
306 Department of Medicine, University of Massachusetts Medical School, AC7-201, 55 Lake Avenue North, 01655, Worcester, MA, USA
307 rdf:type schema:Organization
308 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA
309 schema:name Amgen Inc., One Amgen Center Drive, 91320, Thousand Oaks, CA, USA
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...